Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- MSD Invites Former JPMA Director General as Compliance Adviser
August 15, 2011
- Kowa Obtains Marketing Approval for Pitavastatin in Mexico
August 15, 2011
- Gov't Council Submits 4th Science & Technology Basic Plan
August 15, 2011
- Kyowa Kirin Aims for 70% Increase in Sales for UK Subsidiary ProStrakan by 2013
August 15, 2011
- AZ's New Antiplatelet Agent Ticagrelor Approved by the FDA
August 15, 2011
- Shionogi Completes New Core Research Facility in Toyonaka
August 15, 2011
- Top-100 Product Ranking Affected by Premium, Price Revisions
August 15, 2011
- RoACTEMRA Approved for sJIA in Children 2 Years or Older in Europe
August 15, 2011
- Tella Announces Research Results for Dendritic Cell Vaccine Therapy
August 15, 2011
- Aricept Has Overwhelming Advantage in AD Market in Japan: Mr Honda
August 15, 2011
- Roche's Tarceva Receives Positive Opinion from CHMP for 1st-Line NSCLC Therapy
August 15, 2011
- Korosho Starts Inviting Requests for Approval of Unapproved Drugs/Indications
August 15, 2011
- Yakult Gains Option Rights to Anticancer Drug from Proacta
August 15, 2011
- EC Approves Acquisition of Nycomed by Takeda
August 15, 2011
- First Aid for Choking
August 15, 2011
- Bayer Obtains Exclusive License for Novel Antibiotic
August 15, 2011
- Korosho Taking Public Comments on Proposed GL for Development of Prototype Pandemic Flu Vaccines
August 15, 2011
- Nippon Chemiphar Discontinues Development of NC-2300
August 8, 2011
- Eve No. 1 OTC Analgesic/Antipyretic Drug 3 Months in a Row
August 8, 2011
- R-Tech Ueno Discontinues PI Study of Hypotrichosis Drug in UK
August 8, 2011
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…